SUNITINIB MALATE

Min.Order / FOB Price:Get Latest Price

100 Gram	Negotiable

100 Gram

Negotiable

Min.Order :100 Gram
Purity: 99%
Payment Terms : L/C,T/T,

Keywords

SUNITINIB MALATE N-(2-(Diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide (2S)-hydroxybutanedioate (Z)-N-(2-(diethylaMino)ethyl)-5-((5-fluoro-2-oxoindolin-3-ylidene)Methyl)-2,4-diMethyl-1H-pyrrole-3-carboxaMide (S)-2-hydroxysuccinate

Quick Details

Appearance:Pale yellow to off-white powder
Application:A multi-kinase inhibitor targeting several receptor tyrosine kinases (RTK).
PackAge:as your request
ProductionCapacity:10|Metric Ton|Month
Storage:
Transportation:

Superiority:

Item	Specification	Results
Appearance	Pale yellow to off-white powder	Conforms
Identification	a) IR:IR chromatograph Conforms to the characteristic peak of R.S.	Conforms
Identification	b) HPLC :The retention time of the major peak in the chromatogram Conforms to the characteristic peak of R.S.	Conforms
Residue on ignition	≤ 0.1%	0.07%
Loss on drying	≤1.0%	0.35%
Heavy Metals	≤20 ppm	Conforms
Related substance
Single impurity	≤0.50%	0.22%
Total impurities	≤1.0%	0.61%
Assay[HPLC]	≥99.0%	99.53%
Conclusion	The results comply with standards of enterprise.

Details:

Sunitinib malate is an oral, small-molecule, multi-targeted receptor tyrosine kinase (RTK) inhibitor. Sunitinib malate was approved by the FDA for the treatment of renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST) on January 26, 2006. Sunitinib malate was the first cancer drug simultaneously approved for two different indications.

View All